Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind Study to Investigate the Effects of the Tyrosine Kinase Inhibitor Imatinib on Pulmonary Vascular Dysfunction in a Human Experimental Model of Acute Lung Injury

NCT03328117 is registered in ClinicalTrials.gov with Exvastat Ltd. as lead sponsor.

NCT NCT03328117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind Study to Investigate the Effects of the Tyrosine Kinase Inhibitor Imatinib on Pulmonary Vascular Dysfunction in a Human Experimental Model of Acute Lung Injury
Lead sponsor
Exvastat Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 13, 2017
Completion date
March 5, 2018
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury